Simcha Therapeutics Presents Preclinical Data Demonstrating Potential for Decoy-Resistant IL-18 to Enhance Efficacy of Bi-specific T-cell Engagers Findings presented at European Society for Medical Oncology include models in solid tumors and hematologic malignancies GlobeNewswire October 21, 2025 SOUTH SAN FRANCISCO, Calif., and NEW HAVEN, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) — Simcha Therapeutics (“Simcha”), a […]

New TransUnion Research Reveals Marketers' Confidence in Measurement Has Stalled AI Adoption and long-term ROI strategies on the rise as most marketers face internal skepticism GlobeNewswire October 21, 2025 CHICAGO, Oct. 21, 2025 (GLOBE NEWSWIRE) — Marketers' confidence in measurement has plateaued at a time when it should be rising, according to new research from

Holzer & Holzer, LLC Reminds Investors of Upcoming Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against LifeMD, Inc. (LFMD), Semler Scientific, Inc. (SMLR) and Quantum Corp. (QMCO) GlobeNewswire October 21, 2025 ATLANTA, Oct. 21, 2025 (GLOBE NEWSWIRE) — Holzer & Holzer, LLC reminds investors of the deadline to seek to be appointed lead plaintiff

Glucose Health, Inc. (OTC: GLUC) Announces New Management Appointments and Strategic Outlook GlobeNewswire October 21, 2025 BENTONVILLE, Ark., Oct. 21, 2025 (GLOBE NEWSWIRE) — Glucose Health, Inc. (OTC: GLUC) today announced the appointment of Mark Schaftlein as Chief Executive Officer and member of the Board of Directors, effective October 20, 2025. The Company also announced

Holzer & Holzer, LLC Reminds Investors of Upcoming Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Tronox Holdings plc (TROX), Fly-E Group, Inc. (FLYE), and Savara Inc. (SVRA) GlobeNewswire October 21, 2025 ATLANTA, Oct. 21, 2025 (GLOBE NEWSWIRE) — Holzer & Holzer, LLC reminds investors of the deadline to seek to be appointed lead

Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025 GlobeNewswire October 21, 2025 ~ Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in participants with hypertension and comorbid CKD to be presented~ ~ Phase 3 data

authID Selected by Leading Global Retailer to Launch Biometric-Powered Digital Identity Verification and Password Reset System GlobeNewswire October 21, 2025 DENVER, Oct. 21, 2025 (GLOBE NEWSWIRE) — authID (Nasdaq: AUID) (“authID” or the “Company”), a leading provider of biometric identity verification and authentication solutions, today announced that one of the largest retailers in Europe (the

Cidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation on CD388 at ID Week 2025 GlobeNewswire October 21, 2025 SAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak(R) platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it presented late-breaking Phase 2b clinical data on

Rocket Doctor Expands U.S. Coverage, Becoming In-Network with Two Leading National Insurers With More Than 6.5 Million Additional Members Across California and New York State GlobeNewswire October 21, 2025 These new agreements include approximately 2.7 million members in California under one major insurer and 3.8 million members in New York under two major insurers, extending

Cordia Announces Leadership Realignment to Strengthen National Structure and Drive Growth GlobeNewswire October 21, 2025 Phoenix, AZ, Oct. 21, 2025 (GLOBE NEWSWIRE) — Cordia, a leading provider of energy solutions, announced a series of organizational changes designed to strengthen its national operations, enhance collaboration, and position the company for continued growth and excellence. Over the